SCHEMBL4647372

SCHEMBL4647372

NC(=O)c1ccc(-c2cc(C(F)(F)F)cc(S(=O)(=O)N[C@@H](CO)Cc3c[nH]c4ccccc34)c2)cc1Cl

nearest known ligand 0.48

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
MMP7 P09237 1/20 0.48
NEK1 Q96PY6 2/20 0.48
POLB P06746 1/20 0.44
MMP2 P08253 4/20 0.44
MMP9 P14780 4/20 0.44
NR3C1 P04150 7/20 0.44
NR3C2 P08235 3/20 0.44
PGR P06401 2/20 0.44
MCL1 Q07820 1/20 0.42
ICMT O60725 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4646409 0.91 MEN1 (0.47) MEN1KMT2AMMP7NEK1POLB
SCHEMBL4687933 0.91 MEN1 (0.47) MEN1KMT2AMMP7NEK1POLB
SCHEMBL14025310 0.87 MEN1 (0.43) MEN1KMT2AMMP7NEK1POLB
SCHEMBL4646869 0.82 NEK1 (0.47) MEN1KMT2ANEK1POLBMMP2
SCHEMBL14025315 0.80 NEK1 (0.55) MEN1KMT2AMMP7NEK1POLB
SCHEMBL4647511 0.80 NEK1 (0.52) MEN1KMT2AMMP7NEK1POLB
SCHEMBL4648410 0.79 NEK1 (0.56) MEN1KMT2AMMP7NEK1POLB
SCHEMBL4648789 0.72 NR3C1 (0.49) MEN1KMT2ANEK1POLBMMP2
SCHEMBL4685322 0.72 NR3C1 (0.47) MEN1KMT2ANEK1POLBMMP2
SCHEMBL4647690 0.72 NR3C1 (0.47) MEN1KMT2ANEK1POLBMMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255117-A1 SULFONYLTRYPTOPHANOLS BAYER SCHERING PHARMA AG (DE) 2008-10-16 US claimed
WO-2008104597-A2 SULFONYLTRYPTOPHANOLS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-09-04 WO claimed
EP-1964834-A1 Sulphonyltryptophanols Bayer Schering Pharma Aktiengesellschaft (DE) 2008-09-03 EP claimed
US-20080255117-A1 SULFONYLTRYPTOPHANOLS BAYER SCHERING PHARMA AG (DE) 2008-10-16 US disclosed
US-20080255117-A1 SULFONYLTRYPTOPHANOLS BAYER SCHERING PHARMA AG (DE) 2008-10-16 US disclosed
US-20080255117-A1 SULFONYLTRYPTOPHANOLS BAYER SCHERING PHARMA AG (DE) 2008-10-16 US disclosed
WO-2008104597-A2 SULFONYLTRYPTOPHANOLS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-09-04 WO disclosed
WO-2008104597-A2 SULFONYLTRYPTOPHANOLS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-09-04 WO disclosed
EP-1964834-A1 Sulphonyltryptophanols Bayer Schering Pharma Aktiengesellschaft (DE) 2008-09-03 EP disclosed
EP-1964834-A1 Sulphonyltryptophanols Bayer Schering Pharma Aktiengesellschaft (DE) 2008-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255117-A1 SULFONYLTRYPTOPHANOLS FSHR, NPY1R, GNRHR MEN1 302/4885KMT2A 1685/4885MMP7 2724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.